PBPK Analysis to Study the Impact of Genetic Polymorphism of NAT2 on Drug-Drug Interaction Potential of Isoniazid

被引：0
|
作者：
Ankit Balhara
Saranjit Singh
机构：
[1] National Institute of Pharmaceutical Education and Research (NIPER),Department of Pharmaceutical Analysis
来源：
Pharmaceutical Research | 2021年 / 38卷
关键词：
DDI; genetic polymorphism; isoniazid; N-acetyl transferase; PBPK modeling;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1485 / 1496
页数：11
相关论文
共 50 条
  • [21] A PHYSIOLOGICALLY BASED PHARMACOKINETIC (PBPK) MODEL EVALUATING THE DRUG-DRUG INTERACTION (DDI) POTENTIAL BETWEEN LAMOTRIGINE (LMT) AND ACETAMINOPHEN (APAP).
    Scholz, E.
    Della Pasqua, O.
    Bloomer, J.
    Rebar, L.
    Tracey, H.
    Taskar, K.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2023, 113 : S36 - S37
  • [22] Assessment of drug-drug interaction potential and PBPK modeling of CC-223, a potent inhibitor of the mammalian target of rapamycin kinase
    Tong, Zeen
    Narayanan, Rangaraj
    Atsriku, Christian
    Nissel, Jim
    Li, Yan
    Liu, Hong
    Wang, Xiaomin
    Surapaneni, Sekhar
    XENOBIOTICA, 2019, 49 (01) : 54 - 70
  • [23] The Expression of Recombinant Human CYP2C9 in Saccharomyces Cerevisiae and the Research of Genetic Polymorphism in Drug-Drug Interaction
    Ma, Ping-Ping
    Wang, Hui-Juan
    Zhu, Juan-Li
    Chen, Chao
    DRUG METABOLISM REVIEWS, 2009, 41 : 30 - 31
  • [24] Isoniazid Concentration and NAT2 Genotype Predict Risk of Systemic Drug Reactions during 3HP for LTBI
    Lee, Meng-Rui
    Huang, Hung-Ling
    Lin, Shu-Wen
    Cheng, Meng-Hsuan
    Lin, Ya-Ting
    Chang, So-Yi
    Yan, Bo-Shiun
    Kuo, Ching-Hua
    Lu, Po-Liang
    Wang, Jann-Yuan
    Chong, Inn-Wen
    JOURNAL OF CLINICAL MEDICINE, 2019, 8 (06)
  • [25] The correlation between genetic polymorphisms NAT2 and SLCO1B1 with drug induced hepatotoxicity caused Isoniazid and Rifampicin in tuberculosis patients
    Charisma, Anita Nur
    Soedarsono, Soedarsono
    RESPIROLOGY, 2023, 28 : 50 - 50
  • [26] EVALUATION OF DRUG-DRUG INTERACTION (DDI) POTENTIAL FOLLOWING EPCORITAMAB TREATMENT: RESULTS FROM EXPANSION OF A PHYSIOLOGICALLY BASED PHARMACOKINETIC (PBPK) MODEL
    Li, T.
    Parikh, A.
    Passey, C.
    Sacchi, M.
    Gupta, M.
    Xu, S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S47 - S48
  • [27] A Novel PBPK Modeling Approach to Assess Cytochrome P450 Mediated Drug-Drug Interaction Potential of the Cytotoxic Prodrug Evofosfamide
    Luepfert, Christian
    Dyroff, Martin
    von Richter, Oliver
    Gallemann, Dieter
    El Bawab, Samer
    Dolgos, Hugues
    Jung, Don
    Hecht, Stefan
    Johne, Andreas
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2018, 7 (12): : 829 - 837
  • [28] Cytokine-Mediated Systemic Adverse Drug Reactions in a Drug-Drug Interaction Study of Dolutegravir With Once-Weekly Isoniazid and Rifapentine
    Brooks, Kristina M.
    George, Jomy M.
    Pau, Alice K.
    Rupert, Adam
    Mehaffy, Carolina
    De, Prithwiraj
    Dobos, Karen M.
    Kellogg, Anela
    McLaughlin, Mary
    McManus, Maryellen
    Alfaro, Raul M.
    Hadigan, Colleen
    Kovacs, Joseph A.
    Kumar, Parag
    CLINICAL INFECTIOUS DISEASES, 2018, 67 (02) : 193 - 201
  • [29] USING PBPK MODELING TO EXPLORE THE IMPACT OF ROUTE OF ADMINISTRATION ON THE METABOLIC DRUG-DRUG INTERACTION (DDI) BETWEEN MIDAZOLAM (MDZ) AND FLUCONAZOLE (FLZ).
    Li, M.
    Venitz, J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 97 : S4 - S4
  • [30] Drug-Drug Interaction Potential with Once-Weekly Isoniazid/Rifapentine (3HP) for the Treatment of Latent Tuberculosis Infection
    Marzolini, Catia
    Gibbons, Sara
    van Oosterhout, Joep J.
    Khoo, Saye
    CLINICAL PHARMACOKINETICS, 2022, 61 (03) : 339 - 346
12345